Exasol (EXL) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
11 Nov, 2026Executive summary
Q3 ARR was €37.9m vs. €38.3m a year earlier; new customers and lower churn largely offset weaker upselling.
9M revenue declined mainly because 9M 2025 included exceptionally high one-off hardware and service revenue; recurring revenue was slightly lower YoY.
Financial highlights
9M revenue was €28.7m vs. €31.7m, down 9.5%; recurring revenue was €28.0m vs. €28.5m and non-recurring revenue €0.7m vs. €3.2m.
Q3 revenue was €9.7m vs. €10.2m, down 5%; gross margin was €8.7m vs. €8.9m.
9M EBITDA was €2.7m vs. €3.0m and net income €2.3m vs. €2.1m; Q3 EBITDA was €1.1m vs. €1.0m and net income €1.1m vs. €0.7m.
Q3 new business of €1.1m was offset by a €0.9m contractual MariaDB downsell; net ARR was flat, including €0.5m growth in focus verticals and €0.5m churn in non-focus verticals.
Net liquid funds were €20.6m at Q3-end, vs. €17.7m a year earlier; 12-month cash conversion remained close to 1x EBITDA.
Outlook and guidance
FY2026 guidance was confirmed: ARR change of -2% to +2% vs. Dec. 31, 2025, revenue decline in the upper-single-digit range, and EBITDA of €3.0m–€3.5m; management expects the upper end.
Year-end 2026 churn is expected at 10%; Q1 2027 churn is expected to rise temporarily above 20% on mid-single-digit-million-euro contract cancellations and adjustments.
FY2027 churn is expected at 17%–20%, with Q2–Q4 churn significantly lower; FY2027 guidance is due with FY2026 results in February.
Q1 2027 is expected to be a net ARR decline quarter, with profitability maintained; new business and existing-customer spending recovery are intended to support growth thereafter.
FY2027 priorities include volume upsell, agentic AI cross-selling, partner wins and product-led growth; focus-industry share of ARR is expected to reach 77%–80% after Q1 churn consolidation.
Latest events from Exasol
- Recurring revenue and new customers rose, but revenue and EBITDA fell on weak upsell and delays.EXL
Q2 2026 - ARR decline slowed, churn improved, and 2026 guidance for growth and EBITDA was confirmed.EXL
Q1 2026 TU - 2025 saw robust growth, AI integration, and improved profitability, with ARR set to rise in 2026.EXL
Q4 2025 - EBITDA and net income surged, with focus industries driving ARR growth despite overall ARR decline.EXL
Q4 2025 TU - Revenue up 10.8%, profitability rose, and focus verticals now drive 69% of ARR.EXL
Q2 2025 - Positive EBITDA and double-digit growth achieved, with focus on regulated, hybrid markets.EXL
Q3 2024 TU - Profitable H1 2024 with 12% ARR growth, 9% revenue growth, and strong liquidity.EXL
H1 2024 - Q1 2025 revenue up 25%, profitability surged, focus verticals offset ARR decline.EXL
Q1 2025 TU - First-ever positive EBITDA and net income, with strong sector growth and robust 2025 outlook.EXL
Q4 2024 TU